New Zealand markets closed

Lifecore Biomedical, Inc. (LFCR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.31+0.14 (+2.71%)
At close: 04:00PM EDT
5.28 -0.03 (-0.56%)
After hours: 04:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.17
Open5.23
Bid5.29 x 200
Ask5.38 x 100
Day's range5.07 - 5.36
52-week range3.36 - 11.46
Volume159,198
Avg. volume192,929
Market cap162.204M
Beta (5Y monthly)1.07
PE ratio (TTM)N/A
EPS (TTM)-2.14
Earnings date28 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
  • GlobeNewswire

    Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update

    CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that Ernst & Young LLP, the Company’s independent registered public accounting firm for the fiscal year ended May 28, 2023, determined that it declined to stand for reappointment as the Company’s independent registered public accounting firm for the Company’s fiscal year ending Ma

  • Zacks

    Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal

    Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.

  • GlobeNewswire

    Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

    Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the conclusion of its revi